Joseph Atanasio, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 257 Rt. 22 East, Green Brook, NJ 08812 Phone: 732-968-8832 Fax: 732-968-2187 |
Dr. Suzan Y Khalil, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 275 Greenbrook Rd, Green Brook, NJ 08812 Phone: 732-968-2401 Fax: 732-968-8125 |
Dr. Anandan Devarajan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 230 W End Ave, Green Brook, NJ 08812 Phone: 908-251-5114 Fax: 201-437-2419 |
Yoram Sharon, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1005 North Washington Ave, Green Brook, NJ 08812 Phone: 732-968-8900 Fax: 732-968-4609 |
Syed Fahim Ahmed, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1005 North Washington Ave, Green Brook, NJ 08812 Phone: 732-968-8900 Fax: 732-968-4609 |
News Archive
Biomedical scientist Rajkumar Lakshmanaswamy, Ph.D., has received a $1.1 million research grant from the U.S. Department of Defense to study how early pregnancy reduces a woman's risk for breast cancer.
We meet a multitude of people on a daily basis: the nice waitress in the coffee shop around the corner, the bus driver or the colleagues at the office. Without the ability to recognize faces at first glance we would not be able to distinguish between people. Monkeys also possess the remarkable ability to differentiate faces of group members and to extract the relevant information about the individual directly from the face.
California's insurance exchange came under fire for its plan to withhold quality ratings of health plans until late 2015 while thousands of consumers shop for coverage under the federal healthcare law. The state exchange, Covered California, said Tuesday that it had reliable ratings on only four of the 12 participating health insurers primarily because their networks of doctors and hospitals have changed so much for new policies available next year (Terhune, 10/22).
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec (imatinib).
› Verified 8 days ago